文献速递甲状腺疾病

低危甲状腺癌放射性碘使用与多层次因素相关

Multilevel Factors Associated With More Intensive Use of Radioactive Iodine for Low-Risk Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

这项基于SEER登记的人群调查纳入989例低危分化型甲状腺癌患者,并关联其345名治疗医生。48%患者报告接受放射性碘治疗,23%医生表示会对低危患者使用放射性碘。医生态度与患者接受放射性碘治疗正相关,而医生甲状腺癌患者接诊量较高则与患者接受治疗负相关。

要点

  • 低危甲状腺癌中48%患者报告接受了放射性碘治疗
  • 医生若表示会使用放射性碘,患者接受该治疗的可能性更高
  • 接诊甲状腺癌患者量大的医生,其患者接受放射性碘治疗的几率更低

核心结论

  • 医生对低危甲状腺癌使用放射性碘的观点和态度以及患者接诊量,均影响患者是否接受放射性碘治疗。

研究设计与样本

  • 基于SEER登记(佐治亚州和洛杉矶县)的人群调查,纳入989例低危分化型甲状腺癌患者,关联其345名治疗医生(普外科、耳鼻喉科和内分泌科)。

主要发现

  • 48%的患者报告接受了放射性碘治疗,23%的医生报告会对低危甲状腺癌使用放射性碘。
  • 医生报告会使用放射性碘时,患者报告接受放射性碘的调整OR为1.84(95%CI 1.29-2.61)。
  • 医生接诊甲状腺癌患者量较高(40+ vs 0-20)时,患者报告接受放射性碘的调整OR为0.45(95%CI 0.30-0.67)。

临床怎么用

  • 减少低危甲状腺癌放射性碘过度使用,除患者教育外,还应针对医生态度和观念进行干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The use of radioactive iodine (RAI) for low-risk thyroid cancer is common, and variation in its use exists, despite the lack of benefit for low-risk disease and potential harms and costs. OBJECTIVE: To simultaneously assess patient- and physician-level factors associated with patient-reported receipt of RAI for low-risk thyroid cancer. METHODS: This population-based survey study of patients with newly diagnosed differentiated thyroid cancer identified via the Surveillance Epidemiology and End Results (SEER) registries of Georgia and Los Angeles County included 989 patients with low-risk thyroid cancer, linked to 345 of their treating general surgeons, otolaryngologists, and endocrinologists. We assessed the association of physician- and patient-level factors with patient-reported receipt of RAI for low-risk thyroid cancer. RESULTS: Among this sample, 48% of patients reported receiving RAI, and 23% of their physicians reported they would use RAI for low-risk thyroid cancer. Patients were more likely to report receiving RAI if they were treated by a physician who reported they would use RAI for low-risk thyroid cancer compared with those whose physician reported they would not use RAI (adjusted OR: 1.84; 95% CI, 1.29-2.61). The odds of patients reporting they received RAI was 55% lower among patients whose physicians reported they saw a higher volume of patients with thyroid cancer (40+ vs 0-20) (adjusted OR: 0.45; 0.30-0.67). CONCLUSIONS: Physician perspectives and attitudes about using RAI, as well as patient volume, influence RAI use for low-risk thyroid cancer. Efforts to reduce overuse of RAI in low-risk thyroid cancer should include interventions targeted toward physicians, in addition to patients.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wallner LP, Banerjee M, Reyes-Gastelum D, et al. Multilevel Factors Associated With More Intensive Use of Radioactive Iodine for Low-Risk Thyroid Cancer. J Clin Endocrinol Metab. 2021. PMID: 33687063. doi:10.1210/clinem/dgab139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。